ReviewInternational journal of nanomedicine2026
Engineered Source-Specific Extracellular Vesicles for Neurodegenerative Diseases: From Biological Barriers to Targeted Delivery Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapidly aging global population, neurodegenerative diseases (NDDs) present an escalating challenge to public health. The complex, self-perpetuating pathological network of NDDs, encompassing aberrant protein aggregation, chronic neuroinflammation, synaptic impairment, and mitochondrial dysfunction, significantly impedes the efficacy of traditional single-target pharmacological interventions. Extracellular vesicles (EVs), which encapsulate a diverse array of functional cargoes, including proteins, lipids, and nucleic acids, mediate both horizontal intercellular communication and cross-kingdom signaling. Their distinctive biological properties-characterized by low immunogenicity, favorable biocompatibility, and an intrinsic ability to cross the blood-brain barrier (BBB)-position EVs as a promising multi-target pharmacological platform for treatment of NDDs. By integrating genetic, chemical, and physical engineering strategies, these vesicles have been redefined as programmable nanotherapeutic tools. To address the cost and scalability constraints associated with mammalian cell-derived EVs, plant-derived EV-like nanoparticles (PDENs) represent a promising "green" platform. In this review, we systematically delineate the pathological mechanisms of NDDs, the diverse sources and characteristics of EVs, their functionalization via advanced engineering, and their multifaceted applications in NDDs therapy. Finally, we discuss the translational potential of these platforms, particularly their capacity to address the challenges associated with BBB penetration, and outline a framework to guide the development and clinical evaluation of EV-based therapies for NDDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.